Last year, AstraZeneca reported that a new drug to treat Wilson disease developed by its Alexion rare diseases unit had hit the mark in a phase 3 trial, setting it on course for regulatory filings.

Urinary Copper Outputs of 2 Patients with Wilson's Disease Compared with Those of Patients with Cirrhosis and Normal Subjects. During the patient's 6 months in the hospital on the psychiatric ...

A biochemical diagnosis of Wilson's disease was established in 53 asymptomatic subjects, ranging in age from 15 months to 31 years. None had any pathognomonic physical sign of the disease.

Osteoporosis is a common complication of chronic liver disease. Although bone demineralization has been noted in Wilson's disease—which involves pathologic copper accumulation—the exact ...